Heidi Roschitzki-Voser
Research Subjects
Research Interests
Heidi Roschitzki-Voser has a total of 282 co-authors. Here are the top co-authors by number of shared publications:
- Rolf. A. Stahel
Coordinating Center, ETOP IBCSG Partners Foundation, Bern, Switzerland
9 shared publications Urania Dafni
7 shared publicationsMarkus G. Grütter
Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, Zurich 8057, Switzerland
6 shared publications- Solange Peters
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
6 shared publications Zoi Tsourti
Frontier Science Foundation-Hellas, Athens, Greece
5 shared publicationsB. Ruepp
ETOP IBCSG Partners Foundation, Coordinating Center, Bern, Switzerland
4 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Elsevier in SSRN Electronic Journal
Prognostic value of early FDG-PET/CT response in oligometastatic non-small cell lung cancer: secondary analysis of the ETOP 14-18 CHESS trial
Purpose: Clinical trials in oligometastatic non-small cell lung cancer (NSCLC) have delivered mixed results for adding local ablative therapy to systemic therapy, and prognostic markers to guide patient selection are lacking. In this secondary analysis of the ETOP 14-18 CHESS trial, we assessed the prognostic value of FDG-PET/CT-based response of the primary tumour (PT) and regional lymph node metastases (LN) to metastasis-directed SBRT and chemoimmunotherapy.Methods: ETOP 14-18 CHESS is an international multicentre single-arm phase II trial in synchronous oligometastatic NSCLC. Treatment consisted of upfront SBRT of all distant metastases, with concurrent induction chemoimmunotherapy. Patients without progression underwent local therapy of the PT. The association of baseline tumour burden and clinical parameters with progression-free survival (PFS) from enrolment was assessed using univariate Cox regression. FDG-PET/CT response parameters were similarly assessed using a post-induction approach.Results: Of 49 patients, 45 were analysed for baseline and clinical associations, 41 for early response, and 36 in the post-induction analysis. Baseline cumulative tumour volume was not associated with PFS, whereas low baseline PT SUVmax was (HR 2.29, 95 % CI 1.05-4.98). After induction chemoimmunotherapy, significant volumetric and metabolic responses of the PT and LNs were observed (p-value < 0.001), with no differences between PT and LN changes in either volume or SUVmax (p-value > 0.7). Greater PT SUVmax reduction was associated with longer PFS (HR 0.35, 95 % CI 0.13-0.93). Conclusion: Metabolic response of the PT to induction therapy is associated with favourable outcomes in synchronous oligometastatic NSCLC. FDG-PET/CT-based response assessment warrants prospective evaluation to guide consolidative therapy.
- 16 November 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPrognostic value of early FDG-PET/CT response in oligometastatic non-small cell lung cancer: secondary analysis of the ETOP 14-18 CHESS trial
Purpose: Clinical trials in oligometastatic non-small cell lung cancer (NSCLC) have delivered mixed results for adding local ablative therapy to systemic therapy, and prognostic markers to guide patient selection are lacking. In this secondary analysis of the ETOP 14-18 CHESS trial, we assessed the prognostic value of FDG-PET/CT-based response of the primary tumour (PT) and regional lymph node metastases (LN) to metastasis-directed SBRT and chemoimmunotherapy.Methods: ETOP 14-18 CHESS is an international multicentre single-arm phase II trial in synchronous oligometastatic NSCLC. Treatment consisted of upfront SBRT of all distant metastases, with concurrent induction chemoimmunotherapy. Patients without progression underwent local therapy of the PT. The association of baseline tumour burden and clinical parameters with progression-free survival (PFS) from enrolment was assessed using univariate Cox regression. FDG-PET/CT response parameters were similarly assessed using a post-induction approach.Results: Of 49 patients, 45 were analysed for baseline and clinical associations, 41 for early response, and 36 in the post-induction analysis. Baseline cumulative tumour volume was not associated with PFS, whereas low baseline PT SUVmax was (HR 2.29, 95 % CI 1.05-4.98). After induction chemoimmunotherapy, significant volumetric and metabolic responses of the PT and LNs were observed (p-value < 0.001), with no differences between PT and LN changes in either volume or SUVmax (p-value > 0.7). Greater PT SUVmax reduction was associated with longer PFS (HR 0.35, 95 % CI 0.13-0.93). Conclusion: Metabolic response of the PT to induction therapy is associated with favourable outcomes in synchronous oligometastatic NSCLC. FDG-PET/CT-based response assessment warrants prospective evaluation to guide consolidative therapy.
- 17 October 2025
- Published by Elsevier in Annals of Oncology
- Vol. 37 (2) , 194-205
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
- 17 October 2025
- Published by Elsevier in Annals of Oncology
- Vol. 37 (2) , 194-205
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
- Open Access
- 23 June 2025
- Published by Elsevier in Lung Cancer
- Vol. 206, 108635
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
- 23 June 2025
- Published by Elsevier in Lung Cancer
- Vol. 206, 108635
Open AccessETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
- 21 April 2025
- Published by Elsevier in Lung Cancer
- Vol. 204, 108553
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial
- 21 April 2025
- Published by Elsevier in Lung Cancer
- Vol. 204, 108553
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial
- 21 February 2025
- Published by Elsevier in Lung Cancer
- Vol. 202, 108454
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
- 21 February 2025
- Published by Elsevier in Lung Cancer
- Vol. 202, 108454
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
- Top Cited Papers
- 13 January 2025
- Published by Elsevier in Annals of Oncology
- Vol. 36 (5) , 548-560
A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
- 13 January 2025
- Published by Elsevier in Annals of Oncology
- Vol. 36 (5) , 548-560
Top Cited PapersA randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
- 1 February 2021
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (2) , 278-288
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)
- 1 February 2021
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (2) , 278-288
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)
- 1 October 2020
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (10) , 1647-1656
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
- 1 October 2020
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (10) , 1647-1656
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
- 1 March 2020
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (3) , 416-425
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
- 1 March 2020
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (3) , 416-425
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial